The Chief Financial Officer of Corcept Therapeutics has executed a sale of company stock valued at $2.8 million. This transaction reflects the CFO's decision to divest a portion of their holdings in the company. Details regarding the specific number of shares sold and the timing of the transaction have not been disclosed. Corcept Therapeutics is known for its focus on developing treatments for cancer and other serious disorders.
Related Articles
Don't miss out on breaking stories and in-depth articles.